Eptifibatide

Administration

  • Type: Antiplatelet
  • Dosage Forms: INJ
  • Routes of Administration: IV
  • Common Trade Names: Integrilin

Adult Dosing

Acute Coronary Syndrome

  • 2 mcg/kg/min IV
    • Start 180 mcg/kg up to 22.6 mg IV x1
    • Max: 15 mg/h infusion

PCI

  • 2 mcg/kg/min IV
    • Start 180 mcg/kg up to 22.6 mg IV x1
    • Max: 15 mg/h infusion
    • Repeat bolus x1 10 min after initial dose

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

  • Benefits outweigh risks during pregnancy
  • Risk of maternal hemorrhage during delivery
  • Risk of fetal bleeding

Lactation risk

  • May use when breastfeeding

Renal Dosing

  • Adult:
    • CrCl <50: Decrease infusion to 1 mcg/kg/min, max 7.5 mg/h
    • HD: Avoid use
  • Pediatric: Unavailable

Hepatic Dosing

  • Adult: Not defined
  • Pediatric: Unavailable

Contraindications

  • Allergy to class/drug
  • Bleeding diathesis history
  • Active abnormal bleeding w/in 30 days
  • Major surgery w/in 6 weeks
  • Stroke w/in 30 days
  • Hemorrhagic stroke history
  • Platelet < 100,000
  • SBP > 200, DBP > 110
  • Dialysis

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 2.5 hours
  • Metabolism: Other
  • Excretion: Urine 50%

Mechanism of Action

  • Reversibly binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation

Comments

See Also

References

Authors:

Jonathan Warren